Skip to main content
. 2021 Oct 29;11:21304. doi: 10.1038/s41598-021-00706-8

Figure 4.

Figure 4

EAC PDOs can be used to identify drivers of therapeutic response. (A) Schematic of the RNAseq setup. Created with BioRender.com. (B) Principle component analysis (PCA) of differentially expressed genes with P < 0.02. (C) Venn diagrams of DEGs (P < 0.02) induced by cisplatin or paclitaxel treatments, and the 10 most significantly altered genes are listed. Significance of overlap and fold enrichment as determined by hypergeometric test.